Opinion|Videos|January 10, 2025
Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions
Author(s)Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal residual disease (MRD) as a biomarker across various treatment settings and clinical trials to ensure consistent and reliable use in treatment decision-making.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What, in your opinion, is the definition of the transplant-ineligible population for multiple myeloma?
- With the growing use of MRD as a biomarker, what challenges remain in standardizing its use across different treatment settings and trials?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
COVID Is Back in the Bay Area: Is It the XFG "Stratus" Variant?
2
Zanubrutinib Outlasting Acalabrutinib in CLL
3
Atlanta Panel Confronts Bottlenecks in Alzheimer Disease Diagnosis and Care
4
FITs Offer Lowest Environmental Footprint Among CRC Screening Options
5